Global Biopharmaceutical CDMO Competitive Landscape Professional Research Report 2024

Global Biopharmaceutical CDMO Competitive Landscape Professional Research Report 2024

Research Summary

A biopharmaceutical Contract Development and Manufacturing Organization (CDMO) is a company that provides contract services for the development, manufacturing, and testing of biopharmaceutical products on behalf of pharmaceutical and biotechnology companies. These CDMOs offer a comprehensive range of services, including process development, analytical testing, formulation development, cell line development, and manufacturing of biologics such as monoclonal antibodies, recombinant proteins, vaccines, gene therapies, and cell therapies. By outsourcing these activities to a CDMO, companies can leverage the CDMO＇s expertise, facilities, and resources to accelerate product development, reduce costs, and focus on core competencies while ensuring quality, safety, and compliance with regulatory standards.

According to DIResearch's in-depth investigation and research, the global Biopharmaceutical CDMO market size will reach XX US$ Million in 2024, and is expected to reach XX US$ Million in 2030, with a CAGR of XX% (2025-2030). Among them, the China market has changed rapidly in the past few years. The market size in 2024 will be XX US$ Million, accounting for approximately XX% of the world. It is expected to reach XX US$ Million in 2030, and the global share will reach XX%.

The major global manufacturers of Biopharmaceutical CDMO include Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, WuXi AppTech, Recipharm, Thermo Fisher Scientific, AGC Biologics, Rentschler Biopharma, KBI Biopharma, Siegfried, Aenova Group, GenScript, ProBioGen, Northway Biotech, 3P Biopharmaceuticals etc. The global players competition landscape in this report is divided into three tiers. The first tiers is the global leading enterprise, which occupies a major market share, is in a leading position in the industry, has strong competitiveness and influence, and has a large revenue scale; the second tiers has a certain share and popularity in the market, actively follows the industry leaders in product, service or technological innovation, and has a medium revenue scale; the third tiers has a smaller share in the market, has a lower brand awareness, mainly focuses on the local market, and has a relatively small revenue scale.

This report studies the market size, price trends and future development prospects of Biopharmaceutical CDMO. Focus on analysing the market share, product portfolio, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Biopharmaceutical CDMO market. The report data covers historical data from 2019 to 2023, base year in 2024 and forecast data from 2025 to 2030.

The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Biopharmaceutical CDMO market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Biopharmaceutical CDMO industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.

The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.

Global Key Manufacturers of Biopharmaceutical CDMO Include:

Lonza

Catalent

Samsung Biologics

FUJIFILM Diosynth Biotechnologies

Boehringer Ingelheim

WuXi AppTech

Recipharm

Thermo Fisher Scientific

AGC Biologics

Rentschler Biopharma

KBI Biopharma

Siegfried

Aenova Group

GenScript

ProBioGen

Northway Biotech

3P Biopharmaceuticals

Biopharmaceutical CDMO Product Segment Include:

Cell and Gene Therapies

Antibodies

Vaccines

Other

Biopharmaceutical CDMO Product Application Include:

SMBs

Large Companies

Chapter Scope

Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends

Chapter 2: Global Biopharmaceutical CDMO Industry PESTEL Analysis

Chapter 3: Global Biopharmaceutical CDMO Industry Porter’s Five Forces Analysis

Chapter 4: Global Biopharmaceutical CDMO Major Regional Market Size and Forecast Analysis

Chapter 5: Global Biopharmaceutical CDMO Market Size and Forecast by Type and Application Analysis

Chapter 6: North America Biopharmaceutical CDMO Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 7: Europe Biopharmaceutical CDMO Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 8: China Biopharmaceutical CDMO Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 9: APAC (Excl. China) Biopharmaceutical CDMO Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 10: Latin America Biopharmaceutical CDMO Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 11: Middle East and Africa Biopharmaceutical CDMO Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 12: Global Biopharmaceutical CDMO Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)

Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)

Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers

Chapter 15: Research Findings and Conclusion

Chapter 16: Methodology and Data Sources